SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending downwards following news of a planned bond sale to fund AI investments, sparking concerns about increased spending and potential impact on shareholder value. The community is debating whether the dip presents a buying opportunity, considering the company's fundamentals and long-term growth potential amid the AI push. Some investors are drawing comparisons to past overspending concerns while others see it as a strategic move for future growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit's stock is trending as investors anticipate upcoming earnings, with the community closely watching key metrics like user growth and advertising revenue. Bullish sentiment is fueled by analysts setting higher price targets and highlighting potential from AI and data licensing deals. Short interest is also a key factor being watched.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies behind the OG meme, fueled by a desire to reclaim internet culture. Discussions center on achieving the #1 spot and bringing back the spirit of the 2021 meme era. The community emphasizes belief, teamwork, and rejecting traditional financial analysis in favor of cultural relevance.

Cambium Networks Corp. is a holding company, which engages in the provision of wireless broadband networking infrastructure solutions for network operators. Its products include point-to-point, enterprise Wi-Fi and switching, CCTV, software, and point-to multipoint. The company was founded in 2011 and is headquartered in Hoffman Estates, IL.

Cambium Networks Corp

CMBM is trending due to excitement around its integration with Starlink, with retail traders discussing a potential short squeeze and high trading volume. Community members are debating resistance levels and potential price targets, while also weighing the company's fundamentals and potential for further gains. The stock's volatile price action and significant overnight gains have fueled speculation about its short-term trajectory.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle ($CMG) is trending due to a significant drop following a lowered sales outlook, sparking discussions about consumer spending and the company's value proposition. Community members are debating whether the dip is a buying opportunity or a sign of deeper issues with the brand, citing concerns about pricing, portion sizes, and competition in the fast-casual dining sector.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors anticipate earnings, with community members pointing to the stock's recent strength and potential AI-driven growth. Discussions include Google's partnership with Reliance Jio in India and its increased capital expenditure outlook, with some expecting the stock to test the $300 level. Bullish sentiment is fueled by positive analyst ratings and expectations of a strong quarter.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as it approaches earnings, fueled by optimism around its AI and cloud services. The community is actively discussing the stock's impressive run and debating whether it's overbought, while also noting Google's expansion into new sectors like nuclear energy.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific ($CORZ) is trending as shareholders prepare to vote on a proposed merger with CoreWeave ($CRWV), with many in the community expressing concerns that the deal undervalues $CORZ, particularly given its AI infrastructure potential. Some investors believe that rejecting the deal could lead to a higher valuation for $CORZ as a standalone entity or attract a better offer, while others worry about the company's future prospects without the merger.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

EBS is trending due to raised FY25 EBITDA guidance, sparking optimism about the company's future profitability. The community is discussing the potential for a significant stock re-rating and a short squeeze, with some highlighting the low P/E ratio relative to the broader market. Discussions also involve potential catalysts like government appropriations and debt refinancing.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands, herbicides under the Authority, Boral, Centium, Command, and Gamit brands, insecticides under the Talstar and Hero brands, flutriafol-based fungicides, and bionematicides under the Quartzo and Presence brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMC Corp. is experiencing a significant drop, driven by a dividend cut and lowered full-year earnings expectations, prompting community concern about potential debt issues and bankruptcy. Despite the downturn, some investors view the stock as oversold, anticipating a turnaround as the company focuses on debt reduction. Community members are actively discussing entry points, potential rebound levels, and whether the steep decline is an overreaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Equity

Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

U.S.-listed shares of Birkenstock Holding were up 3% in premarket trading on Thursday, ahead of the German footwear company's quarterly report before the market opens.Analysts expect its third-quarter revenue to rise 19.3%, similar to the preceding two quarters, according to Kofin data. Investors&nbsp;will be watching for comments on the impact of tariffs, price hikes, supply chain disruptions, and the demand landscape in North America and Europe.Piper Sandler, which reaffirmed its 'Overweight' rating this week, noted that unfavorable foreign exchange rates could pressure the company's reported revenue.Birkenstock, known for its clogs or sandals, is in a notably good position. In May, the company raised its annual profit outlook and authorized a $200 million share buyback. Still,&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> are down 11% year-to-date.The stock has gained nearly 6% in the last two sessions, and the latest retail sentiment reading on Stocktwits is ‘extremely bullish,’ signaling investor optimism.<figure class="image"><img style="aspect-ratio:629/72;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_14_at_2_38_43_PM_png_0145047a9b.webp" alt="Screenshot 2025-08-14 at 2.38.43 PM.png" width="629" height="72"><figcaption>BIRK sentiment and message volume as of August 14 | Source: Stocktwits</figcaption></figure>Late last month, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-scores-buy-rating-from-goldman-sachs-shares-rise/choGriXR5vX">raised</a> its rating on Birkenstock to ‘Buy’ from ‘Neutral,’ citing "robust" momentum and an attractive valuation for the company's shares in a challenging&nbsp;macroeconomic backdrop.Footwear companies face broad pressure from U.S. import tariffs on major Asian manufacturing hubs, including China and Vietnam.Swiss company On Holding posted strong quarterly sales and raised its full-year target,&nbsp;attributing the increase to recent price increases on its shoes. In the future, CEO Martin Hoffmann&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/on-holding-ceo-martin-hoffmann-says-the-sportswear-maker-is-in-a-good-position-to-digest-tariffs/chrCS0bRd9p">told</a> Stocktwits that the company is now "in a very good position to digest" the tariffs.Birkenstock also raised prices in the U.S. last month.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various Birkenstock shoes are displayed on shelves in a Birkenstock store on Ehrenstraße. Photo: Rolf Vennenbernd/dpa (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Why Are Birkenstock Shares Rising Premarket?

The move shows optimism ahead of the German footwear company's quarterly report.

Birkenstock Holding (BIRK) shares rose over 1.5% in Thursday's session and another 2% in extended trading, after Goldman Sachs raised its rating on the sandal maker.The research firm raised the rating on the company's shares to 'Buy' from 'Neutral,' while maintaining its $60 price target, according to a summary of the investor note on The Fly. That indicates an over 15% upside to BIRK's last closing price.Currently, 20 of the 22 analysts covering the stock have a 'Buy' or higher rating, and two rate it 'Hold,' according to Koyfin data. Their average price target is $72.26.Goldman Sachs sees "robust" momentum and an attractive valuation for Birkenstock in a challenging macro backdrop. The company has a "strong" product proposition, with pricing power and opportunities to win share in a "highly fragmented" footwear market, the research firm said.Goldman Sachs also noted Birkenstock's vertically integrated manufacturing setup in Europe, which would support the company's margins.Although&nbsp;<a href="https://stocktwits.com/symbol/BIRK">BIRK shares</a> have rebounded over the last couple of weeks, they remain 15.5% below their 2025 peak achieved on Jan. 30.On Stocktwits, retail sentiment shifted to 'neutral' early Friday from 'bearish' the previous day, with several users&nbsp;taking note of the latest upgrade.<figure class="image"><img style="aspect-ratio:1416/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_25_at_10_41_26_AM_png_d52d1b15f5.webp" alt="Screenshot 2025-07-25 at 10.41.26 AM.png" width="1416" height="154"><figcaption>BIRK sentiment and message volume as of July 25 | Source: Stocktwits</figcaption></figure>In May, Birkenstock raised its annual profit outlook and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million share buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chinese-e-commerce-giant-jd-com-could-reportedly-snap-up-media-markt-parent-for-2-6-b-retail-bulls-eye-breakout/choGqh1R5v9">Chinese E-Commerce Giant JD.com Could Reportedly Snap Up MediaMarkt Parent For $2.6B: Retail Bulls Eye Breakout</a>

A Birkenstock shoe displayed on in a Birkenstock store in North Rhine-Westphalia, Cologne, Germany. (Photo by Rolf Vennenbernd/picture alliance via Getty Images)

Birkenstock Scores 'Buy' Rating From Goldman Sachs, Shares Rise 

The sandal maker has "robust" momentum, attractive valuation, and pricing power, the research firm says.

German sandal&nbsp;maker Birkenstock has filed an infringement lawsuit in India's capital, New Delhi, against four footwear traders, four factories, and two unnamed individuals following a company investigation revealed the production, sale, and export of counterfeit products, according to a Reuters report.The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/sustainability/boards-policy-regulation/birkenstock-cracks-down-fakes-india-court-ordered-factory-visits-held-sources-2025-07-06/">report</a>, which cites people familiar with the matter,&nbsp;comes as the footwear industry is garnering increased attention in India. Earlier this month, Crocs (CROX) secured a court nod to pursue a nine-year-old infringement case. At the same time,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/prada-credits-centuries-old-indian-kolhapuri-craftsmanship-behind-open-toe-sandals-design-unveiled-at-milan-show/chmZe7GRReZ">Prada drew criticism</a> after its sandals at a Milan showcase looked nearly identical to Indian Khandasari chappals, prompting the Italian fashion brand to acknowledge the similarity.According to the report, Birkenstock filed the lawsuit in the Delhi High Court in May. It claims that Birkenstock counterfeits were being manufactured in rural areas near the North Indian tourist hub of Agra and sold both locally and exported to other countries. The court has ordered law enforcement inspections of these facilities.India is a key market for the German brand, which last month opened its 50th standalone store in the country,&nbsp;in the financial capital of Mumbai.On Stocktwits, the retail sentiment for BIRK remained 'bullish,' unchanged from a week ago.&nbsp;<a href="https://stocktwits.com/symbol/BIRK">Birkenstock shares</a> are down nearly 14% year-to-date.<figure class="image"><img style="aspect-ratio:615/69;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_2_06_14_PM_png_bdebef4034.webp" alt="Screenshot 2025-07-07 at 2.06.14 PM.png" width="615" height="69"><figcaption>BIRK sentiment and message volume as of July 7 | Source: Stocktwits</figcaption></figure>The development comes at a time of strength for the company. It recently reported strong results for its fiscal second quarter,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-raises-annual-profit-forecast-shares-retail-sentiment-surge/chivoCURbnc">raised its annual profit forecast</a>, and authorized a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/birkenstock-authorizes-200m-buyback-but-retail-remains-cold/ch0AkaLRbti">$200 million buyback</a>.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Birkenstock Reportedly Sues Indian Footwear Makers Over Counterfeits Amid Rising Industry Scrutiny

India is a key market for the German brand, which last month opened its 50th standalone store in the country.

Nasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://argenx.com/news/2024/argenx-announces-european-commission-approval-of-vyvgart--efgart">announced</a> that the European Commission approved its VYVGART 1,000 mg subcutaneous (SC) injection in the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP).CIDP is a rare and often progressive autoimmune disease of the peripheral nervous system. Patients with CIPD experience a range of mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling.The European Commission approved the subcutaneous injection as a monotherapy for patients with the disease who have received prior treatment with corticosteroids or immunoglobulins.The EC approval will apply to all 27 European Union Member States, as well as to Iceland, Liechtenstein, and Norway.VYVGART for SC injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. The company stated that it is “working closely” with local regulatory authorities to ensure patients can access the treatment as soon as possible.The approval is based on a clinical trial that demonstrated 66.5% of patients treated with VYVGART SC showed evidence of clinical improvement, including improvements in mobility, function, and strength. The study also revealed a 61% reduction in the risk of relapse compared to the placebo.This regulatory approval marks the second for VYVGART SC in Europe, which first received approval as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.On Stocktwits, retail sentiment around argenx remained within ‘bullish’ territory over the past 24 hours while message volume remained ‘normal’.<figure class="image"><img style="aspect-ratio:631/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_2_09_51_PM_png_2b09c4d552.webp" alt="ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits" width="631" height="68"><figcaption>ARGX's Sentiment Meter and Message Volume as of 2:10 p.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/ARGX">ARGX stock</a> is down by 12% this year but has gained over 40% in the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-considered-perplexity-acquisition-before-14-3-b-scale-ai-deal/chlxqohRRPz">Meta Reportedly Considered Perplexity Acquisition Before $14.3B Scale AI Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an argenx SE logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail Attention

VYVGART for SC injection is available in vials or prefilled syringes and can be administered by a patient, caregiver, or healthcare professional.

U.K.-based biopharmaceutical company GSK plc (GSK) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older/">said</a> on Friday that the European Medicines Agency (EMA) has accepted its regulatory application to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine to include adults aged 18 years or above.Arexvy is already approved in the European Economic Area for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 and older, and for those aged 50-59 years who are at increased risk for RSV disease due to underlying medical conditions.RSV is a common contagious virus affecting the lungs and breathing passages and impacts an estimated 64 million people of all ages globally every year, GSK said. The virus can aggravate conditions such as asthma and chronic heart failure, leading to hospitalisation and death.The company is looking forward to a decision from the regulator on the application in the first half of 2026.Meanwhile, the firm is continuing to seek an expansion for the treatment scope of its RSV vaccine in geographies including the U.S. and Japan.Arexvy brought in 78 million British pounds ($106.08 million) for GSK in the first quarter of 2025, down 57% from the corresponding period of 2024, following a drop in sales in the U.S., and accounting for just 1% of its overall turnover in the period.On Stocktwits, retail sentiment around GSK remained unmoved within ‘extremely bearish’ territory over the past 24 hours while message volume remained unchanged at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1258/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_12_12_04_PM_png_f36e4b25b0.webp" alt="GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1258" height="126"><figcaption>GSK's Sentiment Meter and Message Volume as of 12:15 p.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure>NYSE-listed shares of GSK are down by 3% as of Friday noon. <a href="https://stocktwits.com/symbol/GSK">The stock</a> is up approximately 22% this year and has increased by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK’s Application To European Authorities For Expanded Use Of RSV Vaccine In Younger Adults Fails To Rejuvenate Retail Optimism

The company is looking forward to a decision from the regulator on the application in the first half of 2026.

Brookfield Asset Management (BAM) has announced a potential investment of up to SEK 95 billion (approximately $10 billion) to develop AI infrastructure in Sweden, marking one of its largest AI initiatives in Europe to date.The funding will be directed toward developing a large-scale AI center in Strängnäs, forming a key component of Sweden’s digital infrastructure aligned with its national AI goals.&nbsp;The facility is expected to grow its capacity from 300 megawatts (MW) to 750 MW, supported by a land deal encompassing around 350,000 square meters.Brookfield expects the Strängnäs facility to create over 1,000 permanent positions, with another 2,000 jobs expected during the 10- to 15-year construction phase.&nbsp;“To compete in the development of AI and realize its economic productivity, it is important to invest at scale in the infrastructure underpinning this technology,” said&nbsp;Head of Europe, Brookfield, Sikander Rashid.According to a Reuters report, the growing adoption of AI and regulations mandating data storage within Europe have sparked a surge in data center development across the region.&nbsp;Companies like Microsoft Inc. (MSFT), Meta Platforms Inc.(META), and Alphabet Inc. (GOOG, GOOGL) have selected Sweden for their facilities, drawn by the country's dependable power supply, infrastructure, and strong connectivity.&nbsp;Brookfield’s AI infrastructure includes more than €100 billion ($114 billion) allocated to areas such as digital connectivity, clean energy, and semiconductor ventures worldwide.&nbsp;In early 2024, the company introduced a €20 billion investment program in France, which features a €10 billion commitment to the country’s inaugural AI manufacturing facility.&nbsp;&nbsp;&nbsp;The New York-based global alternative asset manager oversees over $1 trillion in assets, focusing on long-term investments in real assets and essential service sectors.On Stocktwits, retail sentiment around Brookfield remained in ‘bearish’ territory.<figure class="image"><img style="aspect-ratio:644/74;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_04_083036_png_932e692b08.webp" alt="BAM's Sentiment Meter and Message Volume as of 08:30 a.m. ET on June 4, 2025 | Source: Stocktwits" width="644" height="74"><figcaption>BAM's Sentiment Meter and Message Volume as of 08:30 a.m. ET on June 4, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/BAM">Brookfield</a> stock has gained over 4% year-to-date and over 44% in the last 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/crowdstrike-stock-slumps-post-q1-print-as-analysts-turn-cautious/chkuff6RbwY">CrowdStrike Stock Slumps Post Q1 Print As Analysts Turn Cautious: Retail Seizes Pullback Opportunity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Exchange Rate: 1SEK = 0.10 USD1EUR = 1.14 USD

In this photo illustration, the logo of Brookfield Corporation is displayed on a smartphone screen on April 26, 2025, in Chongqing, China.

Brookfield Commits $10B To Sweden’s AI Expansion: Retail Sees No Reason To Cheer

The AI center in Strängnäs, Sweden, will expand capacity to 750 MW and create 3,000 jobs in the coming years.

German sandals&nbsp;maker Birkenstock Holding (BIRK)&nbsp;said on Wednesday that it plans to buy back $200 million worth of company shares and&nbsp;announced the sale of a block of shares by one of its investors.BK LC Lux MidCo, an entity affiliated with private equity firm L Catterton, is selling 15.7 million shares of Birkenstock at $52.50 a piece. That totals to over $824 million.The shares are being offered to public investors through underwriters in a secondary public offering.Meanwhile, Birkenstock has authorized a $200 million buyback&nbsp;by purchasing an estimated 3.7 million shares. The company's repurchase depends on the progress of the sale by BK LC Lux.Goldman Sachs and JPMorgan are acting as joint book-running managers for the offering.The move comes at a time of strength for the German shoe brand. Earlier this month, Birkenstock reported strong results for the last quarter and raised its annual profit forecast.Revenue rose by a higher-than-expected 19% for its fiscal second quarter, while net profit grew 68%.Birkenstock’s recent performance&nbsp;contrasts with that of other shoe brands, including Nike (NKE) and Crocs, which are grappling with uneven consumer demand following President Donald Trump’s tariff announcements last month.On Stocktwits, the retail sentiment was 'bearish,' unchanged from a month ago.<figure class="image"><img style="aspect-ratio:1276/146;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_29_at_2_30_55_PM_png_e313452594.webp" alt="Screenshot 2025-05-29 at 2.30.55 PM.png" width="1276" height="146"><figcaption>BIRK sentiment and message volume as of May 28 | Source: Stocktwits</figcaption></figure>Birkenstock was listed on the New York Stock Exchange in October 2023.Its shares are down 4.2%% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Birkenstock Authorizes $200M Buyback, But Retail Remains Cold

One of the company's investors is selling over $800 million worth of shares in a secondary market offering.

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.Oncology company Merus on Thursday <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.merus.nl/news-releases/news-release-details/merus-petosemtamab-pembrolizumab-interim-data-demonstrates">said</a> that the combination of bispecific antibody Petosemtamab with Pembrolizumab demonstrated robust efficacy and durability in its ongoing phase 2 trial as of Feb. 27.Merus CEO Bill Lundberg said the data from the trial demonstrates that Petosemtamab in combination with Pembrolizumab can become “a new standard of care" in head and neck cancer and is “significantly better” than treatment with just Pembrolizumab.The company said that as of Feb. 27, 45 patients had been treated in the phase 2 trial, and the combination was generally well tolerated.The CEO also expressed optimism about sharing data from one or both of its late-stage combination trials in 2026.BofA on Friday hiked the price target on Merus to $92 from $70 while keeping a ‘Buy’ rating on the shares. The firm noted that the recently announced data set the combination as "the best-in-class treatment option for this patient population."The analyst’s new price target implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.BMO Capital also hiked the price target on Merus to $110 from $96 on Friday while keeping an ‘Outperform’ rating on the shares. BMO said it sees a 90% probability of the combination's approval for treating head and neck cancer.On Stocktwits, retail sentiment around Merus jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_10_48_55_AM_png_3d759215e6.webp" alt="MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits" width="626" height="63"><figcaption>MRUS's Sentiment Meter and Message Volume as of 10:50 a.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/MRUS">MRUS stock</a> is up by about 30% this year and 25% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jp-morgan-bank-of-america-citigroup-wells-fargo-reportedly-explore-joint-stablecoin/ch0QZ5vRbqs">JPMorgan, Bank of America, Citigroup, Wells Fargo Reportedly Explore Joint Stablecoin</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled

BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.

SSgA Active Trust - SPDR Portfolio Developed World ex-US ETF

Will Amazon.com ($AMZN) beat quarterly earnings? 
 
*Powered by Polymarket

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and other products, including fashion, home, beauty, electronics, Alexa Devices, sporting goods, toys, automotive, pets, baby, books, video games, musical instruments, office supplies, and more.

SPDW
SPDR Portfolio Developed World ex-US ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SPDW News

SPDWSPDR Portfolio Developed World ex-US ETF